Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced the Company will present at two upcoming conferences in March.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin®) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that preclinical data on the efficacy of Supinoxin (RX-5902) alone and in combination with immunotherapy were presented at the 40th Annual San Antonio Breast Cancer Symposium.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 3.27 million shares of its common stock and warrants exercisable for up to approximately 1.63 million shares of its common stock for gross proceeds of $8 million. The shares and warrants are being sold in units, each consisting of one share of common stock and a warrant to purchase 0.5 of a share of common stock, at an offering price of $2.45 per unit. The warrants will be exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date and have an exercise price of $2.85 per share. The closing of the offering is expected to take place on or about October 17, 2017, subject to the satisfaction of customary closing conditions.